Scott H. Okuno

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

Hussein A. Tawbi, Melissa Burgess, Vanessa Bolejack et al. · The Lancet Oncology · 2017 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +13

Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002

Robert G. Maki, J. Kyle Wathen, Shreyaskumar Patel et al. · Journal of Clinical Oncology · 2007 · 733 citations

Medicine, Oncology, Pharmacology +17

Spinal Instability Neoplastic Score: An Analysis of Reliability and Validity From the Spine Oncology Study Group

Daryl R. Fourney, Evan Frangou, Timothy C. Ryken et al. · Journal of Clinical Oncology · 2011 · 541 citations · Full text

Medicine, Oncology, Oncologic Surgery +13

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665

Burton Eisenberg, Jonathan Harris, Charles D. Blanke et al. · Journal of Surgical Oncology · 2008 · 421 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas

Mark Agulnik, Jessica Lee Yarber, Scott H. Okuno et al. · Annals of Oncology · 2012 · 390 citations · Full text

Medicine, Oncology, Surgery +17